Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy
American Journal of Hematology, ISSN: 1096-8652, Vol: 89, Issue: 12, Page: 1121-1131
2014
- 53Citations
- 1Usage
- 111Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations53
- Citation Indexes53
- 53
- CrossRef42
- Usage1
- Abstract Views1
- Captures111
- Readers111
- 111
- Mentions1
- References1
- Wikipedia1
Review Description
Core binding factor acute myelogenous leukemia (CBF AML) constitutes 15% of adult AML and carries an overall good prognosis. CBF AML encodes two recurrent cytogentic abnormalities referred to as t(8;21) and inv (16). The two CBF AML entities are usually grouped together but there is a considerable clinical, pathologic and molecular heterogeneity within this group of diseases. Recent and ongoing studies are addressing the molecular heterogeneity, minimal residual disease and targeted therapies to improve the outcome of CBF AML. In this article, we present a comprehensive review about CBF AML with emphasis on molecular heterogeneity and new therapeutic options.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84922393117&origin=inward; http://dx.doi.org/10.1002/ajh.23821; http://www.ncbi.nlm.nih.gov/pubmed/25088818; https://onlinelibrary.wiley.com/doi/10.1002/ajh.23821; https://stars.library.ucf.edu/scopus2010/8361; https://stars.library.ucf.edu/cgi/viewcontent.cgi?article=9360&context=scopus2010; https://dx.doi.org/10.1002/ajh.23821; https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.23821
Wiley
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know